Spots Global Cancer Trial Database for spms
Every month we try and update this database with for spms cancer trials from around the world to help patients and their families find trials that might be right for them.
We offer this 100% free of charge and do not endorse any of the trials listed here, we hope it helps you or a loved one.
The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.
Study title | NCT ID | Conditions | Interventions | Eligibility | Organization | Link |
---|---|---|---|---|---|---|
Swiss Study of the Impact of Mayzent on SPMS Patients in a Long-term Non-interventional Study | NCT04895202 | Secondary Progr... | Siponimod | 18 Years - | Novartis | |
A Clinical Study of the Efficacy of Natalizumab on Reducing Disability Progression in Participants With Secondary Progressive Multiple Sclerosis | NCT01416181 | Secondary Progr... | natalizumab Placebo | 18 Years - 58 Years | Biogen | |
Exploring the Immune Response to SARS-CoV-2 modRNA Vaccines in Patients With Secondary Progressive Multiple Sclerosis (AMA-VACC) | NCT04792567 | Secondary Progr... | BAF312 Baseline diseas... BNT162 mRNA-1273 | 18 Years - 100 Years | Novartis | |
A Clinical Study of the Efficacy of Natalizumab on Reducing Disability Progression in Participants With Secondary Progressive Multiple Sclerosis | NCT01416181 | Secondary Progr... | natalizumab Placebo | 18 Years - 58 Years | Biogen | |
Safety and Efficacy Study of MIS416 to Treat Secondary Progressive Multiple Sclerosis | NCT02228213 | Secondary Progr... | MIS416 Saline | 18 Years - 70 Years | Innate Immunotherapeutics | |
Long Term Special Drug Use-results Surveillance for Mayzent in SPMS Patients | NCT04593927 | Secondary Progr... | Mayzent | - 99 Years | Novartis | |
Long Term Special Drug Use-results Surveillance for Mayzent in SPMS Patients | NCT04593927 | Secondary Progr... | Mayzent | - 99 Years | Novartis | |
Exploring the Immune Response to SARS-CoV-2 modRNA Vaccines in Patients With Secondary Progressive Multiple Sclerosis (AMA-VACC) | NCT04792567 | Secondary Progr... | BAF312 Baseline diseas... BNT162 mRNA-1273 | 18 Years - 100 Years | Novartis | |
BG00012 and Delay of Disability Progression in Secondary Progressive Multiple Sclerosis | NCT02430532 | Multiple Sclero... | dimethyl fumara... Placebo | 18 Years - 58 Years | Biogen | |
Functional Electrical Stimulation for Individuals With Secondary Progressive Multiple Sclerosis | NCT01647321 | Secondary Progr... | Active cycling Passive cycling | 18 Years - 68 Years | Johns Hopkins University |